Ironwood Pharmaceuticals Inc Revenue Growth Rates (IRWD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ironwood Pharmaceuticals inc   (NASDAQ: IRWD)
 

IRWD's Revenue Growth by Quarter and Year

Ironwood Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IRWD/growth
https://api.csimarket.com/api/v1/companies/IRWD/fundamentals
https://api.csimarket.com/api/v1/companies/IRWD/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IRWD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 133.04
2nd Quarter June 113.04
1st Quarter March 106.51
FY 352.59

IRWDs Annual Revenue
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 296.15 millions
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 351.41 millions
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 442.74 millions
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 410.60 millions
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 413.75 millions




IRWD Revenue third quarter 2026 Y/Y Growth Comment
Ironwood Pharmaceuticals inc reported Revenue growth of 9% year on year in the third quarter 2026, to $ 133.04 millions, this is lower than Ironwood Pharmaceuticals Inc 's recent average Revenue improvement of 32.37%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 127 other companies have achieved higher Revenue growth. While Ironwood Pharmaceuticals Inc ' s Revenue increase of 9% ranks overall at the positon no. 2841 in the third quarter 2026.


IRWD Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 9 %
2nd Quarter June 32.61 %
1st Quarter March 158.9 %
FY   -

Financial Statements
Ironwood Pharmaceuticals Inc 's third quarter 2026 Revenue $ 133.04 millions IRWD's Income Statement
Ironwood Pharmaceuticals Inc 's third quarter 2025 Revenue $ 122.06 millions Quarterly IRWD's Income Statement


IRWD Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 17.69 %
2nd Quarter June 6.13 %
1st Quarter March 123.24 %
FY (Year on Year)   -


Back to IRWD Growth rate Comparisons >> Back to IRWD Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #128
Healthcare Sector #406
Overall #2841

Revenue Y/Y Growth Statistics
High Average Low
255.54 % 32.37 % -84.77 %
(Jun 30 2015)   (Dec 31 2013)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #128
Healthcare Sector #406
Overall #2841
Revenue Y/Y Growth Statistics
High Average Low
255.54 % 32.37 % -84.77 %
(Jun 30 2015)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ironwood Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
560.18 % 23.72 % -87.94 %
(Sep 30 2012)  


IRWD's III. Quarter Q/Q Revenue Comment
Ironwood Pharmaceuticals inc achieved in the III. Quarter 2026 below company average Revenue jump of 17.69% quarter on quarter, to $ 133.04 millions.

Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue quarter on quarter growth. While Ironwood Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1064.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #159
Overall #1064
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #159
Overall #1064
Revenue Q/Q Growth Statistics
High Average Low
560.18 % 23.72 % -87.94 %
(Sep 30 2012)  


IRWD's III. Quarter Q/Q Revenue Comment
Ironwood Pharmaceuticals inc achieved in the III. Quarter 2026 below company average Revenue jump of 17.69% quarter on quarter, to $ 133.04 millions.

Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue quarter on quarter growth. While Ironwood Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1064.


Ironwood Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 400.30
Y / Y Revenue Growth (TTM) 18.09 %
Year on Year Revenue Growth Overall Ranking # 3455
Seqeuential Revenue Change (TTM) 2.82 %
Seq. Revenue Growth (TTM) Overall Ranking # 2888


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Ironwood Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 400 millions, company would post below average annual Revenue growth of 2.82% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Ironwood Pharmaceuticals Inc 's Revenue growth from the 113.04% growth in Jun 30 2026.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3218 to 3455.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 128
Healthcare Sector # 460
Overall # 3455

Revenue TTM Y/Y Growth Statistics
High Average Low
255.54 %
 32.37 %
-84.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 128
Sector # 406
S&P 500 # 2888
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Ironwood Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 400 millions, company would post below average annual Revenue growth of -84.77% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Ironwood Pharmaceuticals Inc 's Revenue growth from the 113.04% growth in Jun 30 2026.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3218 to 3455.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 128
Healthcare Sector # 460
Overall # 3455

Revenue TTM Y/Y Growth Statistics
High Average Low
255.54 %
32.37 %
-84.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 128
Sector # 406
S&P 500 # 2888




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IRWD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions


About Ironwood Pharmaceuticals Inc Revenue Growth Rates (IRWD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ironwood Pharmaceuticals Inc (CIK 1446847).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-123319
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ironwood Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.